CA
NZ
UK
AU
IND
US
Africa's energy vulnerability to the Hormuz conflict reflects both the continent's dependence on imported petroleum products and the particular supply chains through which those products have historically been procured. East African countries including Kenya, Tanzania, and Ethiopia have been most directly affected by the …
Iran'sInvestmentin non-state proxy forces across the Middle East and beyond represents decades of patient strategic development that has created an instrument of power projection that conventional military forces cannot easily destroy. The proxy network operates across multiple countries simultaneously, requires relatively modest Iranian resource …
Every military conflict that extends beyond its initial phase faces the exit strategy problem: how does the initiating power define success in a way that allows it to disengage without appearing to have lost? For the Trump administration and the Iran conflict, this problem …
Trump's observation that rate cuts may have to wait until the Iran war is over is analytically correct but strategically complicated. The Iran conflict is, as the president notes, the primary driver of the energy price inflation that has pushed headline CPI to 3.8% …
The immediate case for dollar strength in the current environment is straightforward: the US yield differential against major currencies provides a carry trade incentive that attractsCapitalflows to dollar-denominatedAssets. When US ten-year yields are significantly above equivalent European, Japanese, or UK yields, international investors earn …
A quarter defined by execution, not macro recovery
Key HighlightsTraditional drug discovery takes 12 years and costs over $2 billion per approved drug, with a 90% clinical trial failure rate that AI is systematically addressing.AlphaFold solved the protein folding problem in structural biology, unlocking decades of compounding scientific progress that will fundamentally …
Skye Bioscience, Inc. announced that the Cohort Review Committee unanimously approved the opening of Cohort 2 in the CBeyond Part C Expansion study, allowing escalation of nimacimab dosing to 600 mg intravenously once weekly.
Why Arm Holdings (NASDAQ: ARM) Stock Is Rallying Ahead of Nvidia Earnings
Why Immunovant, Inc. (NASDAQ: IMVT) Is Pivoting Toward IMVT-1402
Please wait processing your request...